Institute of Medicine fails to recommend automatic Medicare reimbursement of most device clinical trials.
This article was originally published in Clinica
A report mandated by US Congress on the reimbursement of routine costs for Medicare patients enrolled in clinical trials has failed to recommend any changes in the way it pays for most device clinical trials.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.